These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 25234022)

  • 1. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer.
    Rossi L; Santoni M; Crabb SJ; Scarpi E; Burattini L; Chau C; Bianchi E; Savini A; Burgio SL; Conti A; Conteduca V; Cascinu S; De Giorgi U
    Ann Surg Oncol; 2015 Apr; 22(4):1377-84. PubMed ID: 25234022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
    Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
    Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
    Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
    Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy.
    Tanaka N; Kikuchi E; Kanao K; Matsumoto K; Shirotake S; Miyazaki Y; Kobayashi H; Kaneko G; Hagiwara M; Ide H; Obata J; Hoshino K; Hayakawa N; Kosaka T; Hara S; Oyama M; Momma T; Nakajima Y; Jinzaki M; Oya M
    Ann Surg Oncol; 2014 Nov; 21(12):4041-8. PubMed ID: 24912614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio.
    Ferroni P; Riondino S; Formica V; Cereda V; Tosetto L; La Farina F; Valente MG; Vergati M; Guadagni F; Roselli M
    Int J Cancer; 2015 Mar; 136(5):1234-40. PubMed ID: 25042739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy.
    Luo G; Guo M; Liu Z; Xiao Z; Jin K; Long J; Liu L; Liu C; Xu J; Ni Q; Yu X
    Ann Surg Oncol; 2015 Feb; 22(2):670-6. PubMed ID: 25155401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-lymphocyte ratio is a simple and novel biomarker for prediction of survival after radioembolization for metastatic colorectal cancer.
    Tohme S; Sukato D; Chalhoub D; McDonald KA; Zajko A; Amesur N; Orons P; Marsh JW; Geller DA; Tsung A
    Ann Surg Oncol; 2015 May; 22(5):1701-7. PubMed ID: 25190128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of prognosis using the neutrophil-lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
    BJU Int; 2015 Apr; 115(4):587-94. PubMed ID: 24947340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery.
    Forget P; Machiels JP; Coulie PG; Berliere M; Poncelet AJ; Tombal B; Stainier A; Legrand C; Canon JL; Kremer Y; De Kock M
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S650-60. PubMed ID: 23884751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated preoperative systemic inflammatory markers predict poor outcome in localized soft tissue sarcoma.
    Choi ES; Kim HS; Han I
    Ann Surg Oncol; 2014 Mar; 21(3):778-85. PubMed ID: 24306668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.
    Sun J; Ning H; Sun J; Qu X
    Urol Oncol; 2016 May; 34(5):239.e9-15. PubMed ID: 26803433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer.
    Tan YG; Eu EWC; Huang HH; Lau WKO
    Int J Urol; 2018 Mar; 25(3):232-238. PubMed ID: 29094397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative neutrophil to lymphocyte ratio predicts survival in patients with T1-2N0 colorectal cancer.
    Shin JS; Suh KW; Oh SY
    J Surg Oncol; 2015 Nov; 112(6):654-7. PubMed ID: 26437893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Ability of Blood Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Gastrointestinal Stromal Tumors.
    Racz JM; Cleghorn MC; Jimenez MC; Atenafu EG; Jackson TD; Okrainec A; Venkat Raghavan L; Quereshy FA
    Ann Surg Oncol; 2015 Jul; 22(7):2343-50. PubMed ID: 25472648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.
    Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S
    Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies.
    Wu S; Zhao X; Wang Y; Zhong Z; Zhang L; Cao J; Ai K; Xu R
    Cell Physiol Biochem; 2018; 46(4):1352-1364. PubMed ID: 29689562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.